An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), which has a global prevalence of 20%–33%, has become the main cause of chronic liver disease. Except for lifestyle medication, no definitive medical treatment has been established so far, making it urgent to find effective strategies for the treatment of NA...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-05-01
|
| Series: | Engineering |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095809920302721 |
| _version_ | 1819009481238904832 |
|---|---|
| author | Mingfei Yao Lingling Qv Yanmeng Lu Baohong Wang Björn Berglund Lanjuan Li |
| author_facet | Mingfei Yao Lingling Qv Yanmeng Lu Baohong Wang Björn Berglund Lanjuan Li |
| author_sort | Mingfei Yao |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD), which has a global prevalence of 20%–33%, has become the main cause of chronic liver disease. Except for lifestyle medication, no definitive medical treatment has been established so far, making it urgent to find effective strategies for the treatment of NAFLD. With the identification of the significant role played by the gut microbiota in the pathogenesis of NAFLD, studies on probiotics for the prevention and treatment of NAFLD are increasing in number. Bacteria from the Bifidobacterium and Lactobacillus genera constitute the most widely used traditional probiotics. More recently, emerging next-generation probiotics (NGPs) such as Akkermansia muciniphila and Faecalibacterium prausnitzii have also gained attention due to their potential as therapeutic options for the treatment of NAFLD. This review provides an overview of the effects of oral administration of traditional probiotics and NGPs on the development and progress of NAFLD. The mechanisms by which probiotics directly or indirectly affect the disease are illustrated, based on the most recent animal and clinical studies. Although numerous studies have been published on this topic, further research is required to comprehensively understand the specific underlying mechanisms among probiotics, gut microbiota, and NAFLD, and additional large-scale clinical trials are required to evaluate the therapeutic efficacy of probiotics for the treatment of NAFLD, as well as the safety of probiotics in the human body. |
| first_indexed | 2024-12-21T00:57:03Z |
| format | Article |
| id | doaj.art-8090d3f53c3e46f584f87f7fa0385473 |
| institution | Directory Open Access Journal |
| issn | 2095-8099 |
| language | English |
| last_indexed | 2024-12-21T00:57:03Z |
| publishDate | 2021-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Engineering |
| spelling | doaj.art-8090d3f53c3e46f584f87f7fa03854732022-12-21T19:21:16ZengElsevierEngineering2095-80992021-05-0175679686An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver DiseaseMingfei Yao0Lingling Qv1Yanmeng Lu2Baohong Wang3Björn Berglund4Lanjuan Li5State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, ChinaState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China; Department of Clinical and Experimental Medicine, Linköping University, Linköping SE 581 83, SwedenState Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China; Corresponding author.Non-alcoholic fatty liver disease (NAFLD), which has a global prevalence of 20%–33%, has become the main cause of chronic liver disease. Except for lifestyle medication, no definitive medical treatment has been established so far, making it urgent to find effective strategies for the treatment of NAFLD. With the identification of the significant role played by the gut microbiota in the pathogenesis of NAFLD, studies on probiotics for the prevention and treatment of NAFLD are increasing in number. Bacteria from the Bifidobacterium and Lactobacillus genera constitute the most widely used traditional probiotics. More recently, emerging next-generation probiotics (NGPs) such as Akkermansia muciniphila and Faecalibacterium prausnitzii have also gained attention due to their potential as therapeutic options for the treatment of NAFLD. This review provides an overview of the effects of oral administration of traditional probiotics and NGPs on the development and progress of NAFLD. The mechanisms by which probiotics directly or indirectly affect the disease are illustrated, based on the most recent animal and clinical studies. Although numerous studies have been published on this topic, further research is required to comprehensively understand the specific underlying mechanisms among probiotics, gut microbiota, and NAFLD, and additional large-scale clinical trials are required to evaluate the therapeutic efficacy of probiotics for the treatment of NAFLD, as well as the safety of probiotics in the human body.http://www.sciencedirect.com/science/article/pii/S2095809920302721Non-alcoholic fatty liver disease (NAFLD)Gut microbiotaProbioticsNext-generation probiotics (NGPs) |
| spellingShingle | Mingfei Yao Lingling Qv Yanmeng Lu Baohong Wang Björn Berglund Lanjuan Li An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease Engineering Non-alcoholic fatty liver disease (NAFLD) Gut microbiota Probiotics Next-generation probiotics (NGPs) |
| title | An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_full | An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_fullStr | An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_full_unstemmed | An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_short | An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease |
| title_sort | update on the efficacy and functionality of probiotics for the treatment of non alcoholic fatty liver disease |
| topic | Non-alcoholic fatty liver disease (NAFLD) Gut microbiota Probiotics Next-generation probiotics (NGPs) |
| url | http://www.sciencedirect.com/science/article/pii/S2095809920302721 |
| work_keys_str_mv | AT mingfeiyao anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT linglingqv anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT yanmenglu anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT baohongwang anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT bjornberglund anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT lanjuanli anupdateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT mingfeiyao updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT linglingqv updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT yanmenglu updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT baohongwang updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT bjornberglund updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease AT lanjuanli updateontheefficacyandfunctionalityofprobioticsforthetreatmentofnonalcoholicfattyliverdisease |